GSK joins AstraZeneca, Boehringer in capping US out-of-pocket …

Mar 21, 2024 · The move follows similar announcements from GSK's peers Boehringer Ingelheim and AstraZeneca. Each drugmaker is capping out-of-pocket costs at $35 per month for their …

CouponFollow Extension

$35
OFF

GSK Joins AstraZeneca, Boehringer In Capping US Out-of-pocket …

2 weeks from now

Mar 21, 2024 · The move follows similar announcements from GSK's peers Boehringer Ingelheim and AstraZeneca. Each drugmaker is capping out-of-pocket costs at $35 per month for their …

fiercepharma.com

$35
OFF

GSK Announces Cap Of $35 Per Month On U.S. Patient Out-of …

2 weeks from now

Mar 20, 2024 · Announcement builds on GSK’s decades-long commitment to making products accessible to those who need them; GSK today announced it will cap out-of-pocket costs for …

gsk.com

$35
OFF

Third Inhaler Company Caps Prices At $35 A Month After Baldwin’s ...

2 weeks from now

Mar 21, 2024 · WASHINGTON, D.C. – U.S. Senator Tammy Baldwin (D-WI) applauds GlaxoSmithKline’s (GSK) announcement that Americans throughout the country with asthma …

senate.gov

$35
OFF

AstraZeneca To Cap Out-of-pocket Inhaler Costs In US, Following …

2 weeks from now

Mar 18, 2024 · AZN. (Reuters) -Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from …

yahoo.com

$35
OFF

Following Boehringer's Lead, AstraZeneca ⁠caps Monthly Out-of …

2 weeks from now

Mar 18, 2024 · The plan is to cap monthly out-of-pocket drug costs for eligible patients at $35. The move will kick in on June 1 and includes inhaled medicines for both asthma and chronic …

fiercepharma.com

$35
OFF

GSK Follows Rivals, To Cap Out-of-Pocket Inhaler Cost In US

2 weeks from now

Mar 21, 2024 · GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals …

nasdaq.com

$35
OFF

AstraZeneca Caps Patient Out-of-pocket Costs At $35 Per Month …

2 weeks from now

Mar 18, 2024 · AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their …

astrazeneca-us.com

$35
OFF

Boehringer Ingelheim Caps Patient Out-of-pocket Costs For Its …

2 weeks from now

Ridgefield, Conn., March 7, 2024 – Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patients i for all the company’s inhaler products. …

boehringer-ingelheim.com

$35
OFF

AstraZeneca To Cap Out-of-pocket Inhaler Costs In US, Following …

2 weeks from now

March 18 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, …

reuters.com

$35
OFF

GSK Joins Boehringer And AstraZeneca In Capping Out-of-pocket …

2 weeks from now

Mar 21, 2024 · GSK will cap out-of-pocket costs for its inhalers at $35, making it the third major drugmaker to agree to limit patients’ spending amid significant US political pressure over the …

sfbn.org

$35
OFF

GSK To Cap Out-of-pocket Inhaler Costs In US

2 weeks from now

Mar 21, 2024 · British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for …

bworldonline.com

$35
OFF

GSK Joins Boehringer And AstraZeneca In Capping Out-of-pocket …

2 weeks from now

Mar 21, 2024 · GSK will cap out-of-pocket costs for its inhalers at $35, making it the third major drugmaker to agree to limit patients’ spending amid significant US ….

endpts.com

$35
OFF

Boehringer To Cap Out-of-pocket Inhaler Cost At $35 Per Month

2 weeks from now

Mar 7, 2024 · Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German …

reuters.com

FAQs about GSK joins AstraZeneca, Boehringer in capping US out-of-pocket … Coupon?

Is GSK the third major inhaler manufacturer to cap prices?

GSK becomes third major inhaler manufacturer to cap prices after increased scrutiny from Baldwin; Baldwin: “Make no mistake, our campaign against big drug companies to lower costs is working” ...

Is AstraZeneca following Boehringer Ingelheim?

AstraZeneca is following Boehringer Ingelheim's lead and taking a step to boost patient access in the U.S. by capsizing out-of-pocket costs for its inhaler portfolio at $35 per month. (Getty/AntonioGuillem) Earlier this month, Boehringer Ingelheim capped out-of-pocket costs for its own inhaler portfolio in the U.S. ...

Is GSK capping patients' monthly payments for COPD Meds?

(GlaxoSmithKline) Amid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giant to commit to capping patients' monthly payments for its portfolio of asthma and chronic obstructive pulmonary disease (COPD) meds. The move follows similar announcements from GSK's peers Boehringer Ingelheim and AstraZeneca. ...

What is the GSK out-of-pocket price cap?

The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35. Maya Martinez-Davis, President, U.S. Commercial, GSK said: “GSK is committed to bringing innovation and accessibility to patients with respiratory illnesses. ...

Does AstraZeneca have a cap on inhalers?

This cap would apply to all of AstraZeneca’s inhaled respiratory products, which include Airsupra, Bevespi Aerosphere, Breztri Aerosphere and Symbicort. However, the company plans not to start this until June 2024. The British drugmaker is one of the biggest sellers of inhalers in the United States. ...

Are Boehringer & AstraZeneca inhalers cheaper?

One of the biggest manufacturers of inhalers in the United States, Boehringer’s inhaled respiratory portfolio includes Atrovent, Combivent, Spiriva, Stiolto and Striverdi. AstraZeneca and Boehringer’s aggressive price cuts come amid pressure to cut costs of asthma inhalers to make them affordable for American citizens. ...